In addition, suppression of BIM expression causes NSCLC TKI resistance (Tetsu et al., 2016), whereas PARP-1 inhibitor presents a therapeutic strategy for TKI resistance in NSCLC (Li et al., 2016). Here, BCL2L11 is linked to non-small cell lung carcinoma.